CSS
NVCT icon

Cubist Systematic Strategies’s Nuvectis Pharma NVCT Stock Holding History

Cubist Systematic Strategies’s Portfolio NVCT Stock Details NVCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-6,294
Closed -$34.1K – 3314
2024
Q4 		$34.1K Buy
+6,294
New +$39.4K ﹤0.01% 2816

Other funds holding NVCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BWP
Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JMFC
J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
AWM
Austin Wealth Management Austin, Texas $473M AUM 18.73% 1-Year Est. Return

Cubist Systematic Strategies's NVCT Position: Q1 2025 in Review

Cubist Systematic Strategies sold out of Nuvectis Pharma (NVCT) in Q1 2025, closing a stake of 6,294 shares — an estimated $34.1K sold.

Cubist Systematic Strategies first reported a position in NVCT in Q4 2024 and held it in 1 quarter. The position peaked at $34.1K in Q4 2024. 33 funds tracked by Wall St. Rank hold NVCT as of Q1 2025.

  • Cubist Systematic Strategies reported no remaining Nuvectis Pharma position as of Q1 2025 after selling out during the quarter.
  • Cubist Systematic Strategies sold 6,294 Nuvectis Pharma shares in Q1 2025, an estimated $34.1K.
  • Cubist Systematic Strategies first reported a position in Nuvectis Pharma in Q4 2024 and held it in 1 quarter.
  • Cubist Systematic Strategies's Nuvectis Pharma position peaked at $34.1K in Q4 2024.
  • 33 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q1 2025.

Based on Cubist Systematic Strategies's 13F filing for Q1 2025, filed 15 May 2025.